A comprehensive offer across the leukemia R&D value chain
From basic research to real-world clinical studies, OPALE offers a one-stop shop for your research and development projects aimed at creating new therapeutic and diagnostic solutions for leukemias and related diseases, regardless of your company's size or the nature of your project.
Discover our R&D offers and partnership opportunities tailored to your objectives
Discover all our integrated R&D offers and our preclinical models catalog. To find a specific offer matching your needs, you can use the search engine below, or export our entire catalog*.
*Export generation may take a few seconds.
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (AML)
NATIONAL CLINICAL RESEARCH NETWORK TO SUPPORT SPONSORS OF PHASE I TO IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (AML)
DATA AND SAMPLES FROM ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
NATIONAL CLINICAL RESEARCH NETWORK TO SUPPORT DRUG RESEARCH AND DEVELOPMENT (AML)
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (CLL/WM/AML/MPS)
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS - COLLABORATION (CLL/WM/AML/MPS)
PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIAL DATABASES (MPN/CLL/WM/AML)
HEMATOLOGICAL MALIGNANCIES BIOBANK (CLL/AML)
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE II TO IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (ALL)
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I TO III INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (MDS)
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN AND CONDUCT OF PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS IN CHILDHOOD AND ADOLESCENT LEUKEMIA (AML/ALL/MPS/MDS)
COHORT GENOMIC ANNOTATION PLATFORM FOR PHASE I TO III CLINICAL TRIALS (AML/MDS/LEUKEMIA PREDISPOSITION SYNDROMES)
PLATFORM FOR GENOMIC ANNOTATION AND RETROSPECTIVE ANALYSIS OF AML COHORTS
CLINICAL INVESTIGATION CENTER FOR THE SPONSORING AND CONDUCT OF PHASE I TO III INTERVENTIONAL CLINICAL TRIALS (ALL/AML/MPS/MDS)
CLINICAL INVESTIGATION CENTER FOR THE COORDINATION AND CONDUCT OF PHASE I TO III CLINICAL TRIALS IN LEUKEMIA AND RELATED DISEASES (AML, MPS, MDS, ALL)
PLATFORM FOR DEVELOPING AND IMPLEMENTING TESTS FOR PRECLINICAL VALIDATION IN VITRO, EX VIVO, AND IN VIVO (ACUTE LEUKEMIA)
PLATFORM FOR ACCELERATING THE DISCOVERY AND OPTIMIZATION OF NEW BIOACTIVE MOLECULES (ACUTE LEUKEMIA)
ROLE OF PPAR-Y IN HEMATOPOIESIS AND THE BONE MARROW ENVIRONMENT: PRECLINICAL MODELS AND TESTS (MPN)
MODELS FOR PRECLINICAL STUDIES OF THE IMPACT OF BONE MARROW FIBROSIS ON THE NATURAL HISTORY OF HEMOPATHIES (MPN)
CLINICAL TRIALS CENTER FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I TO IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS IN LEUKEMIA (CML, AML, ALL)
IN VITRO EVALUATION OF THE EFFECTS OF ANTILEUKEMIC DRUGS IN A MODELED LEUKEMIC NICHE WITH OPTIMIZED BONE MARROW MICROENVIRONMENT (MSCS, HYPOXIA, PRESSURE) (MPN/ALL/AML/MDS)
METABOLIC, GENOMIC, TRANSCRIPTOMIC AND FUNCTIONAL ANALYSES OF THE LEUKEMIC NICHE FOR PHASE 1 TRIALS (MPN/ALL/AML/MDS)
PLATFORM FOR SCREENING MOLECULES ABLE OF REPROGRAMMING PRIMARY HUMAN MACROPHAGES (AML/Myelofibrosis/MDS/CMML)
PLATFORM FOR THE ISOLATION OF ORGANELLES IN LEUKEMIA CELLS TO ASSESS FUNCTIONAL MODULATIONS LINKED TO PATHOLOGY OR CHEMOTHERAPEUTIC TREATMENT (AML/MDS/CMML)
CHARACTERIZATION OF CELL DEATH IN LEUKEMIA CELLS TO ASSESS THE EFFICACY OF THERAPEUTIC SOLUTIONS IN THE TREATMENT OF MYELOID LEUKEMIA (AML/MDS/CMML)
IN CELLULO IDENTIFICATION OR VALIDATION OF THERAPEUTIC TARGETS IN MYELOID LEUKEMIA USING CLICK CHEMISTRY TECHNOLOGY TO DEVELOP NEW DIAGNOSTIC METHODS OR TARGETED THERAPIES
PHARMACODYNAMIC STUDIES FOR THE DEVELOPMENT OF NEW TREATMENTS FOR ACUTE MYELOID LEUKEMIA
PRECLINICAL MOUSE MODELS FOR NEW MOLECULES SCREENING IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA B
PRECLINICAL XENOGRAFT MODELS FOR THE EVALUATION OF NEW COMPOUNDS IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA B
DEVELOPMENT OF MOLECULAR DIAGNOSTICS KITS FOR GENOMIC ALTERATION IN LEUKEMIA AND OTHER MALIGNANT HEMOPATHIES
STUDIES OF THE MECHANISM OF HEMATOPOIETIC STEM CELL TRANSFORMATION IN ACUTE MYELOID LEUKEMIA AND CLONAL SELECTION MODELS
ARTIFICIAL INTELLIGENCE-AUGMENTED CELLULAR IMAGING IN ACUTE MYELOID LEUKEMIA (DIAGNOSIS, PROGNOSIS, STRATIFICATION)
DEVELOPMENT OF IMMUNOTHERAPIES TARGETING THE CYTOTOXIC ACTIVITY OF NK CELLS (ALL/MDS)
IN VIVO MODEL OF WALDENSTRÖM DISEASE
STUDY OF IMMUNE CELL BIOLOGY IN RESPONSE TO TREATMENT IN AML/MDS/WM PATIENTS
RAINBOW PLATFORM: PHARMACODYNAMIC MONITORING BY SINGLE-CELL OMICS
NEXT PLATFORM: DRUG COMBINATION SCREENING OF PRIMARY SAMPLES FOR ACUTE MYELOID LEUKEMIA
IN VITRO TRANSLATIONAL STUDIES FOR THE DEVELOPMENT OF DIFFERENTIATING TARGETED THERAPIES FOR ACUTE MYELOID LEUKEMIA
IN VITRO AND IN VIVO MODELS FOR STUDYING THE FUNCTIONAL GENETICS OF ACUTE MYELOID LEUKEMIA IN CHILDREN
STUDY OF MOLECULAR MECHANISMS REGULATING NORMAL AND MALIGNANT HEMATOPOIESIS (AML)
INVESTIGATING THE MECHANISM OF ACTION OF DRUG CANDIDATES FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
PRECLINICAL MODELS FOR THE DEVELOPMENT OF NEW TREATMENTS FOR MYELOPROLIFERATIVE NEOPLASIA
LEUKEMIC NICHE MODELING (AML)
DEVELOPMENT OF NEW TARGETED THERAPIES FOR ACUTE MYELOID LEUKEMIA
PLATFORM FOR MULTIOMIC ANALYSIS OF HEMATOPOIESIS OR THE IMMUNE SYSTEM IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES OR AFTER CSH ALLOGRAFT (ALL/AML/MPS/MDS)
MOUSE MODELS FOR THE STUDY OF GRAFT-VERSUS-HOST DISEASE (GVHD) OR GRAFT-VERSUS LEUKEMIA (GVL) (ALL/AML)
CLINICAL AND PRECLINICAL EVALUATION OF EFFICACY AND TOXICITY OF CAR-T CELL (ALL/AML) TREATMENTS
PRECLINICAL STUDIES FOR THE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA
PRECLINICAL STUDY OF HEMATOPOIETIC SYSTEM REGENERATION FOLLOWING EXPOSURE TO GENOTOXIC STRESS SUCH AS IRRADIATION AND CHEMOTHERAPY (ALL/AML)
PRECLINICAL TESTING OF CAR-T CELLS FOR THE TREATMENT OF T/B ACUTE LYMPHOBLASTIC LEUKEMIA
DEVELOPMENT OF SMALL MOLECULES FOR TARGETED THERAPIES (ALL/AML)
MANUFACTURING OF ADVANCED THERAPY DRUGS: EARLY CLINICAL TRIALS OF CAR-T CELLS (ALL/AML)
MANUFACTURING OF INNOVATIVE THERAPY DRUGS: PROCESS OPTIMIZATION AND INDUSTRIALIZATION (ALL/AML)